| Subscribe To Our Free Newsletter |
Piramal Pharma stock hits new, soars 25% in 6 days on strong Q2 results
Over the long term, the management remains committed to achieving the company's financial goals of $2 billion revenue with 25 per cent EBITDA margin and 1x net debt / EBITDA by FY30.
